Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

6 Nov 2013 12:08

RNS Number : 3570S
Advanced Oncotherapy PLC
06 November 2013
 



ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

 

Issue of Equity

 

Advanced Oncotherapy (AIM: AVO) announces that it has conditionally placed 15,625,000 new ordinary shares (the "New Ordinary Shares") of the Company at a subscription price of 3.2 pence per New Ordinary Share to raise £0.5 million before expenses. The shares have been placed with three institutional investors.

 

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that trading will commence on or about 12 November 2013. The New Ordinary Shares will rank pari passu in all aspects with the existing ordinary shares of the Company. On admission, the total number of ordinary shares in issue will be 604,441,502.

 

 

 

For further information, please visit www.advancedoncotherapy.comor contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson/Lucy Williams

Simon Hudson

Advanced

Oncotherapy Plc

Libertas Capital

Corporate Finance Ltd

Peterhouse

Corporate Finance

Tavistock Communications

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

+44 20 3617 8739

+44 20 3697 9495

+44 20 7469 0930

+44 20 7920 3150

 

 

About Advanced Oncotherapy Plc

 

1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

 

2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

 

3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

-ends-

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOELQLFBXFFBFBD
Date   Source Headline
11th Dec 20067:01 amRNSAcquisition
13th Sep 20067:04 amRNSSenior Management Appointment
8th Sep 20067:01 amRNSInterim Results
4th Sep 20063:48 pmRNSPreferred Bidder Status
9th Aug 20061:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.